Eli Lilly and Company

United States of America Country flag United States of America
Sector: Pharmaceuticals
Ticker: LLY
Factsheet Factsheet

Market multiple valuation of Eli Lilly and Company ( LLY | USA)

The most common multiple used in the valuation of stocks is the P/Earnings NTM multiple (Price to Earnings). P/E relates the current share price with the market expectations in terms of Earnings Per Share. This multiple is used to compare a company's market value with its earnings. A company with a high P/Earnings NTM is considered to be overvalued; a company with a low P/Earnings NTM is considered to be undervalued.
The P/Earnings NTM ratio of Eli Lilly and Company is significantly higher than the median of its peer group: around 12.00. The company valuation of Eli Lilly and Company according to these metrics is way above the market valuation of its peer group.
The P/Earnings NTM ratio of Eli Lilly and Company is significantly higher than the average of its sector (Pharmaceuticals): 8.54. The company valuation of Eli Lilly and Company according to these metrics is way above the market valuation of its sector.
The P/Earnings NTM ratio of Eli Lilly and Company is lower than its historical 5-year average: 35.3. The (current) company valuation of Eli Lilly and Company is therefore below its valuation average over the last five years.

Valuation
P/E Last P/E (e) 2025P/E NTM
Eli Lilly and CompanyFree trialFree trialFree trial
International PeersFree trialFree trialFree trial
Pharmaceuticals-0.117.618.54
DJIA24.6618.3417.19
United States of America0.6511.3011.28
More...
Beta (Ref: DJIA)
Levered betaUnlevered beta
1-Year0.330.33
2-Year0.490.48
3-Year0.580.56
More...
Stock Perf excl. Dividends (in USD)
LLYDJIARel. Perf.
Year-to-Date0.6%-3.4%4.0%
1-Week-13.6%1.1%-14.7%
1-Month7.3%8.3%-1.0%
1-Year-0.1%5.7%-5.9%
3-Year161.6%25.0%136.6%
5-Year407.8%72.2%335.6%
More...
International Peers - Eli Lilly and Company
Company NameCtryMarket
Cap.
last (mUSD)
Eli Lilly and CompanyUSA737 352
International Peers Median0.81
Pfizer Inc.USA127 989
Merck & Co., Inc.USA200 554
GlaxoSmithKline plcGBR-0.00
AstraZeneca PLCGBR-0.00
Novartis AGCHE-0.00
GPRV Analysis
Created with Highcharts 4.1.70/102/104/106/108/1010/10
Eli Lilly and Compan...
Intl. Peers
U.S Patents No. 7,882,001 & 8,082,201
More...
Net Sales Chart
Created with Highcharts 4.1.7Millions USD201920202021202220232024 (e)2025 (e)2026 (e)2027 (e)0k50k100k
More...
Quotes Chart

1-Year Rebased Stock Chart

  • Eli Lilly and Company
  • DJIA
Created with Highcharts 4.1.7Jan '25Sep '24May '25-10%0%10%20%30%
More...

Did you know ?

Multiples charts provide an effective way to quickly analyze a company's valuation over a period of time, and compare it against the valuation of another company, a personal list, or a market index.

About Market Multiples

Many methods can be used to value a company. In reality, business valuation is often a combination of these different approaches. One of the most widely used quantitative methods is the market multiples method. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business.
Current multiples include:
- Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM);
- Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1.
Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).